The latest news from Israeli scientists, published in the Times of Israel, is that researchers at Tel Aviv University have accurately targeted cancerous cells in mice using CRISPR.…
A study conducted by researchers from the Institute of Cancer Research in London and Cyclacel has recently been published in PLOS ONE. This investigation examined fadraciclib as a potential therapy…
One huge goal throughout the medical world is to find effective and well-tolerated treatments for patients with cancer. According to News Medical, researchers recently discovered one beneficial treatment for…
An NIH news release shared that a study on polycystic ovarian syndrome (polycystic ovary syndrome or PCOS) discovered that the condition might have two distinct subtypes based on genetic mutations. Through…
In her early 20's, Mackenzie Alleman lost her mother to breast cancer. Then, at 28, she herself underwent a preventative double mastectomy after learning that she carried the mutated BRCA1 gene.…
Merck and AstraZeneca recently announced that Lynparza improved overall survival in the lives of males with advanced prostate cancer who had been treated previously. The drug out-performed two other antiandrogen…
A recent release from Yale University highlights research from Dr. Kutluk Oktay, a fertility expert, on how BRCA-mutated breast cancer may affect fertility following chemotherapy treatments. His findings suggest that women…
Primary Peritoneal Cancer (PPC) What is primary peritoneal cancer?Primary peritoneal cancer (PPC) occurs in the lining of organs in the abdomen, called the peritoneum. It can occur in any of the…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
